More than 40,000 people will participate in the “large-scale” clinical trials of the COVID-19 vaccine that Russia has already registered and that are being opened to other countries to expand the market, some of which have already shown interest in Take participate in both the test phase and the production phase.
The director-general of the Russian Direct Investment Fund Kiril Dimitriev has announced that the trials will begin next week and will “be fully in line with international standards” after the onslaught of registration brought international experts on the alert who question the vaccine’s effectiveness, called Sputnik V.
The tests will initially begin in Russia while making the jump to other countries in either late August or early September. In the case of Russia, the studies will coincide with the vaccination of people who are considered to be a risk group, such as health or educational staff, according to the Sputnik news agency.
“We can start delivering the vaccine to overseas markets in November or December this year, and we expect mass vaccination in Russia to start in October,” he said.